NetSig: network-based discovery from cancer genomes

NetSig is a network-based statistic that identifies cancer driver genes with high accuracy and can be combined with gene-based statistical tests; results are validated with a large-scale in vivo tumorigenesis assay. Methods that integrate molecular network information and tumor genome data could com...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Nature methods 2018-01, Vol.15 (1), p.61-66
Hauptverfasser: Horn, Heiko, Lawrence, Michael S, Chouinard, Candace R, Shrestha, Yashaswi, Hu, Jessica Xin, Worstell, Elizabeth, Shea, Emily, Ilic, Nina, Kim, Eejung, Kamburov, Atanas, Kashani, Alireza, Hahn, William C, Campbell, Joshua D, Boehm, Jesse S, Getz, Gad, Lage, Kasper
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:NetSig is a network-based statistic that identifies cancer driver genes with high accuracy and can be combined with gene-based statistical tests; results are validated with a large-scale in vivo tumorigenesis assay. Methods that integrate molecular network information and tumor genome data could complement gene-based statistical tests to identify likely new cancer genes; but such approaches are challenging to validate at scale, and their predictive value remains unclear. We developed a robust statistic (NetSig) that integrates protein interaction networks with data from 4,742 tumor exomes. NetSig can accurately classify known driver genes in 60% of tested tumor types and predicts 62 new driver candidates. Using a quantitative experimental framework to determine in vivo tumorigenic potential in mice, we found that NetSig candidates induce tumors at rates that are comparable to those of known oncogenes and are ten-fold higher than those of random genes. By reanalyzing nine tumor-inducing NetSig candidates in 242 patients with oncogene-negative lung adenocarcinomas, we find that two ( AKT2 and TFDP2 ) are significantly amplified. Our study presents a scalable integrated computational and experimental workflow to expand discovery from cancer genomes.
ISSN:1548-7091
1548-7105
DOI:10.1038/nmeth.4514